Numerous studies (in vivo and in vitro) showed that PUFAs are effective inhibitors of HMG-R activity and are useful in the treatment of hyperlipidemia and hypercholesterolemia (El-Sohemy and Archer, 1997[63], 1999[62]; Duncan et al., 2005[59]; Das, 2001[54]; Nakamura et al., 1998[147]). The gene discussed is HMGA1; the disease is familial hypercholesterolemia.